2021-2030 Analysis and Review Type 1 Hyperlipoproteinemia Drugs Market
Type 1 Hyperlipoproteinemia Drugs Market By Indication (Hypertriglyceridemia, Pancreatitis, Eruptive Xanthomas and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The Type 1 hyperlipoproteinemia drugs market was valued at USD958.2Mn by 2019. As per the latest statistics provided by the National Organization for Rare Disorders (NORD), the global prevalence rate of type 1 hyperlipoproteinemia is 1 to 2 per 1,000,000 people. Strong product pipeline with revolutionary drugs will be employed in the treatment of type 1 hyperlipoproteinemia in the near future.
Type 1 hyperlipoproteinemia is also known as familial lipoprotein lipase deficiency, it is classified as a rare monogenetic rare disease in which there is excessive accumulation of triglycerides and chylomicrons in the human blood. Currently there is no FDA approved treatment regimen for this rare disease, however, drugs such as Alipogene Tiparvovec, lomitapide mesylate, pradigastat sodium, etc. are successfully employed in the treatment of type 1 hyperlipoproteinemia.
The major segments related to the type 1 hyperlipoproteinemia drugs market are:
By Indication (2017–2027; US$ Mn)
Hypertriglyceridemia
Pancreatitis
Eruptive Xanthomas
Others
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment(2017–2027; US$ Mn)
North America
United States
Canada
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
Significant customers?
Segment Analysis
Hypertriglyceridemia is reigning the indication segment for the type 1 hyperlipoproteinemia drug market. The inherent deficiency of the triglyceride metabolizing enzyme lipoprotein lipase causes the accumulation of triglyceride and chylomicrons in the blood plasma. It untreated presents risks for the occurrence of cardiovascular disease in the later parts of life. Acute pancreatitis is the first visible symptoms in patients suffering from lipoprotein lipase enzyme deficiency. The patients suffer from excruciating pain due to inflammation of the pancreas, if untreated it may be life-threatening and increases the risk of diabetes. Eruptive Xanthomas occurs in approximately 50% of the patients suffering from type 1 hyperlipoproteinemia, it is manifested by the occurrence of small bumps, or plaques on the skin surface due to localized deposition of lipids in the tendons, skin and subcutaneous tissues.
Hospital pharmacy is spearheading the distribution channel segment for the type 1 hyperlipoproteinemia drug market. Hospital pharmacist is necessary to compound the vital drugs prescribed for the treatment of orphan disease, in order to negate the occurrence of any drug-related adverse effects. Retail pharmacy is gaining huge demand in the developing countries on account of dispensing prescribed and OTC medicines 24/7 especially in remote locations.
North America is currently the largest geographical segment for the type 1 hyperlipoproteinemia drug market. As per the latest information brought forward by the National Institute of Health (NIH), annually in the United States more than 37,000 citizens are diagnosed with acute pancreatitis. Further diagnosis has revealed that it is linked with high levels of triglycerides in the blood. Proactive role adopted by the USFDA by awarding fast track designation status for the drug development to be used in the treatment of orphan disease further propels the type 1 hyperlipoproteinemia drug market. The market growth in the European region is primarily determined by the strategic research coloration between the academic research institutes and biopharmaceutical companies for drug development to treat lipoprotein lipase disorders. Additionally affordable reimbursement scenario for the drugs employed in the treatment of type 1 hyperlipoproteinemia accentuates its market growth in the region. Asia Pacific will be the fastest-growing regional segment during the forecast period owing to the developing healthcare infrastructure and huge government funds invested in research and development of orphan drugs.
$4,600 | |
$6,600 | |
$9,500 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |